 HOUSTON and CAMBRIDGE, Mass., July 28, 2021 PRNewswire -- The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation NASDAQ: BPMC today announced a three-year strategic research collaboration focused on accelerating development of BLU-222, an investigational precision therapy designed to target cyclin-dependent kinase 2 CDK2. 